menu
    • menu
    [{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Cyprium Therapeutics"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Cyprium Therapeutics"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Fortress","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Fortress"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Copper Histidine","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"AAV-ATP7A","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Cyprium Therapeutics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Cyprium Therapeutics \/ National Institute of Neurological Disorders and Stroke"}]

    Find Clinical Drug Pipeline Developments & Deals by Cyprium Therapeutics

    Menu

    Cyprium Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-ATP7A,Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : $4.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Fortress Biotech and Cyprium Announce Grant from NINDS for AAV-ATP7A Gene Therapy

                            Details : The funding is intended to aid in the finalization of Cyprium's primary candidate, currently undergoing preclinical trials involving AAV-ATP7A in conjunction with CUTX-101 for Menkes Disease.

                            Brand Name : AAV-ATP7A

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 04, 2024

                            Lead Product(s) : AAV-ATP7A,Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : $4.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Sentynl Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histi...

                            Details : Under the agreement, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 (copper histidinate) product candidate for the treatment of Menkes disease, to Sentynl.

                            Brand Name : CUTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Sentynl Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to...

                            Details : CUTX-101, a subcutaneous injectable formulation of Copper Histidinate has potential to be first FDA-approved treatment for Menkes disease; rolling submission of New Drug Application to FDA is ongoing and expected to be completed in mid-year 2022.

                            Brand Name : CUTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2022

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Pr...

                            Details : In two completed open-label, single-arm, single-site studies, 129 patients with Menkes disease were treated with CUTX-101 administered subcutaneously twice daily until 12 months of age, and once daily thereafter, for a total duration of up to three years...

                            Brand Name : CUTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2021

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Sentynl Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics and Sentynl Therapeutics Sign Development and Asset Purchase Agreement

                            Details : Sentynl has signed an agreement with Cyprium to contribute research funding for CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease, and to purchase Cyprium's proprietary rights to CUTX-101.

                            Brand Name : CUTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            February 24, 2021

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Sentynl Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Cyprium Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fortress Biotech Gets Positive Opinion on Orphan Drug Designation Received from the EMA for CUTX-101

                            Details : Orphan Drug Designation in the European Union (“EU”) is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products.

                            Brand Name : CUTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2020

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth